Stabilized formulations of CNS compounds
First Claim
Patent Images
1. A pharmaceutical formulation comprising molindone as a single active pharmaceutical ingredient and having:
- (a) a modified-release formulation comprising;
(i) molindone,(ii) at least one release controlling polymer, wherein the release controlling polymer (1) consists of one or more pH-dependent polymers selected from the group consisting of poly (methyl acrylate-co-methyl methacrylate-co-methacrylic acid), poly (methacrylic acid-co-methyl methacrylate), methacrylic acid-ethyl acrylate copolymer, methacrylic acid-ethyl acrylate copolymer dispersion, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, and zein and (2) does not comprise non-pH-dependent polymers, and(iii) at least one stabilizer selected from the group consisting of acidifying agents and hydrophobizing agents; and
, optionally,(b) an additional formulation comprising molindone in an immediate release, extended release, or delayed release formulation.
1 Assignment
0 Petitions
Accused Products
Abstract
Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone.
-
Citations
22 Claims
-
1. A pharmaceutical formulation comprising molindone as a single active pharmaceutical ingredient and having:
-
(a) a modified-release formulation comprising; (i) molindone, (ii) at least one release controlling polymer, wherein the release controlling polymer (1) consists of one or more pH-dependent polymers selected from the group consisting of poly (methyl acrylate-co-methyl methacrylate-co-methacrylic acid), poly (methacrylic acid-co-methyl methacrylate), methacrylic acid-ethyl acrylate copolymer, methacrylic acid-ethyl acrylate copolymer dispersion, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, and zein and (2) does not comprise non-pH-dependent polymers, and (iii) at least one stabilizer selected from the group consisting of acidifying agents and hydrophobizing agents; and
, optionally,(b) an additional formulation comprising molindone in an immediate release, extended release, or delayed release formulation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
Specification